RxDoctor Payments Data

Lonnie Joe, MD

Internal Medicine · Southfield, MINPI 1972657260

Payments from drug & device makers

$15,730in general payments, 2019–2025

Across 448 payments — averaging $35.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$4K
  • AstraZeneca$2K
  • Novo Nordisk$2K
  • GSK$846
  • Teva Pharmaceuticals USA, Inc.$824
  • Regeneron Healthcare Solutions, Inc.$586
  • plus $5K from 42 others

What the payments were for

  • Speaking & faculty fees$2,61117%
  • Travel & lodging$9016%
  • Food & beverage$12,20178%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,730 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$91,757
Medicare patients
146
Services billed
1,287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TracleerBosentan13$165,881
Trelegy ElliptaFluticasone/Umeclidin/Vilanter118$86,013
JardianceEmpagliflozin60$64,656
EliquisApixaban55$51,355
OzempicSemaglutide35$39,561
Breztri AerosphereBudesonide/Glycopyr/Formoterol61$37,798
TrulicityDulaglutide12$11,371
Spiriva HandihalerTiotropium Bromide13$11,197
Tiotropium Bromide19$10,397
LinzessLinaclotide16$9,954
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$7,107
JanumetSitagliptin Phos/Metformin Hcl11$5,781
Theophylline ErTheophylline Anhydrous29$5,338
SymbicortBudesonide/Formoterol Fumarate24$5,257
Colchicine26$3,813

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Tracleer$119$165,88113 claims
GSKTrelegy Ellipta$846$86,013118 claims
Boehringer IngelheimJardiance$129$64,65660 claims
PfizerEliquis$3,995$51,35555 claims
AstraZenecaBreztri Aerosphere, Symbicort$2,169$43,05485 claims
Novo NordiskOzempic$2,004$39,56135 claims
Lilly USA, LLCTrulicity$478$11,37112 claims
AbbVieLinzess$509$9,95416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Southfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →